Pantera Silver hit with BCSC cease-trade order over delayed annual filings
Bitget2026/10/06 13:07British Columbia Securities Commission issued a failure-to-file cease trade order on Oct. 5, 2026, halting trading where effective. Order follows delayed audited annual financial statements for the year ended May 31, 2026, including MD&A and CEO/CFO certifications. Filing delay tied to extra time needed to obtain, reconcile, and verify financial records for Bolivian entities and operations. Cease trade order remains until the annual filings are completed and regulators revoke the order. Exploration work continues, including activity in Bolivia’s Rakanco Silver District, despite the trading halt. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pantera Silver Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610060907NEWSFILECNPR____20261006_317638_1) on October 06, 2026, and is solely responsible for the information contained therein.
- British Columbia Securities Commission issued a failure-to-file cease trade order on Oct. 5, 2026, halting trading where effective.
- Order follows delayed audited annual financial statements for the year ended May 31, 2026, including MD&A and CEO/CFO certifications.
- Filing delay tied to extra time needed to obtain, reconcile, and verify financial records for Bolivian entities and operations.
- Cease trade order remains until the annual filings are completed and regulators revoke the order.
- Exploration work continues, including activity in Bolivia’s Rakanco Silver District, despite the trading halt.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
